WINTON GROUP Ltd Acquires 53,607 Shares of Dynavax Technologies Corporation $DVAX

WINTON GROUP Ltd increased its holdings in Dynavax Technologies Corporation (NASDAQ:DVAX) by 93.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 111,187 shares of the biopharmaceutical company’s stock after buying an additional 53,607 shares during the quarter. WINTON GROUP Ltd’s holdings in Dynavax Technologies were worth $1,104,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Hantz Financial Services Inc. boosted its stake in shares of Dynavax Technologies by 236.9% during the 3rd quarter. Hantz Financial Services Inc. now owns 3,854 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 2,710 shares during the last quarter. LSV Asset Management bought a new position in Dynavax Technologies in the 3rd quarter worth $89,000. Osaic Holdings Inc. lifted its position in Dynavax Technologies by 15.1% during the second quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 1,226 shares in the last quarter. Summit Global Investments bought a new stake in Dynavax Technologies during the third quarter valued at about $113,000. Finally, Catalyst Funds Management Pty Ltd purchased a new stake in Dynavax Technologies in the second quarter worth about $121,000. 96.96% of the stock is currently owned by institutional investors.

Insider Transactions at Dynavax Technologies

In other news, COO David F. Novack sold 114,000 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $15.64, for a total transaction of $1,782,960.00. Following the sale, the chief operating officer directly owned 63,344 shares of the company’s stock, valued at $990,700.16. This represents a 64.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.98% of the stock is currently owned by insiders.

Dynavax Technologies Stock Performance

Shares of DVAX stock opened at $15.50 on Thursday. Dynavax Technologies Corporation has a 12-month low of $9.20 and a 12-month high of $15.73. The company has a current ratio of 7.62, a quick ratio of 6.94 and a debt-to-equity ratio of 0.41. The stock’s 50-day moving average price is $15.51 and its 200-day moving average price is $12.41. The stock has a market capitalization of $1.82 billion, a price-to-earnings ratio of -41.89 and a beta of 0.97.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on DVAX. Wall Street Zen raised Dynavax Technologies to a “strong-buy” rating in a research report on Saturday, February 14th. William Blair cut Dynavax Technologies from an “outperform” rating to a “hold” rating in a research report on Wednesday, December 24th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Dynavax Technologies in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Reduce” and a consensus target price of $21.00.

About Dynavax Technologies

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.